Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sitagliptin/Metformin Tablets in Healthy Chinese Subjects
NCT07910682Phase 1Completed
- Sponsor
- Guangzhou Panyu District Central Hospital
- Start
- Feb 2025
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 cohorts), sponsored by Guangzhou Panyu District Central Hospital. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve from time zero to last quantifiable concentration at 48 hours and 1 more. Started Feb 2025; status: completed.
02
Drugs
sitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07910682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910682.